On 6 and 7 October, the Vall d’Hebron Institute of Oncology (VHIO) hosted the kick-off meeting of the GLIOLIFE-AECC project….
AECC
A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy Cancer neoantigens and neoantigen-specific T…
Results from the phase 3 TALAPRO-3 trial show that the combination of enzalutamide and talazoparib reduces the risk of progression…
Investigators from VHIO, which is part of the Vall Hebron Campus, publish the first study to address the impact of…
After more than a decade of research, a new-generation CAR-T therapy developed by VHIO, in collaboration with the Hospital del…
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy…
From November 6 to 7, 2025, VHIO hosted the first SOSCLC-AECC Annual Symposium at the “Pabellón Docente” of the Vall d’Hebron Campus. The event brought…
Following the success of its inaugural edition, the Vall d’Hebron Institute of Oncology (VHIO), in partnership with the BBVA Foundation,…
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by…
Now published in Annals of Oncology (1), updated meta-analysis provides insights into the efficacy of adoptive cell therapy with tumor-infiltrating…
